- Home
- ACON vs CDT Comparison
ACON vs CDT Comparison
Compare ACON & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- CDT
- Stock Information
- Founded
- ACON 2008
- CDT 2019
- Country
- ACON United States
- CDT United States
- Employees
- ACON N/A
- CDT N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- CDT Health Care
- Exchange
- ACON Nasdaq
- CDT Nasdaq
- Market Cap
- ACON 4.5M
- CDT 4.6M
- IPO Year
- ACON 2022
- CDT N/A
- Fundamental
- Price
- ACON $7.30
- CDT $1.68
- Analyst Decision
- ACON Buy
- CDT
- Analyst Count
- ACON 2
- CDT 0
- Target Price
- ACON $481.00
- CDT N/A
- AVG Volume (30 Days)
- ACON 12.7K
- CDT 81.6K
- Earning Date
- ACON 08-14-2025
- CDT 08-14-2025
- Dividend Yield
- ACON N/A
- CDT N/A
- EPS Growth
- ACON N/A
- CDT N/A
- EPS
- ACON N/A
- CDT N/A
- Revenue
- ACON $62,948.00
- CDT N/A
- Revenue This Year
- ACON $145.39
- CDT N/A
- Revenue Next Year
- ACON $145.45
- CDT N/A
- P/E Ratio
- ACON N/A
- CDT N/A
- Revenue Growth
- ACON 16.68
- CDT N/A
- 52 Week Low
- ACON $6.20
- CDT $1.47
- 52 Week High
- ACON $3,499.51
- CDT $274.80
- Technical
- Relative Strength Index (RSI)
- ACON 50.24
- CDT 38.23
- Support Level
- ACON $7.00
- CDT $1.47
- Resistance Level
- ACON $7.75
- CDT $1.85
- Average True Range (ATR)
- ACON 0.44
- CDT 0.11
- MACD
- ACON 0.01
- CDT 0.02
- Stochastic Oscillator
- ACON 47.06
- CDT 48.84
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.